Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease
Open accessAbstract
Background & aims There are few data from prospective studies on the effects of aspirin on fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).Methods We performed a prospective cohort study of 361 adults with biopsy-confirmed NAFLD, from 2006 through 2015, examined every 3-12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). Histologic analyses of liver biopsies collected at baseline were performed by a blinded pathologist. Information collected at baseline and at each examination included frequency and duration of aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Using multivariable-adjusted logistic regression, we estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis. Using multivariable-adjusted Cox proportional hazards modeling, we estimated the association between aspirin use and risk for fibrosis progression.Results At enrollment, 151 subjects used aspirin daily. Compared with non-regular use, daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68; 95% CI, 0.37-0.89) and fibrosis (adjusted odds ratio, 0.54; 95% CI, 0.31-0.82). Among individuals with baseline F0-F2 fibrosis (n = 317), 86 developed advanced fibrosis over 3692 person-years. Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43-0.85). This relationship appeared to be duration dependent (adjusted P trend=.026), with the greatest benefit found with at least 4 years or more of aspirin use (aHR, 0.50; 95% CI, 0.35-0.73). Conversely, use of nonaspirin NSAIDs was not associated with risk for advanced fibrosis (aHR, 0.93; 95% CI, 0.81-1.05).Conclusions In a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of cardiometabolic comorbidities may modify disease progression and contribute to a reduction in liver-related events (e.g. statins, aspirin, renin-angiotensin-aldosterone modulators).
“Treatment of cardiometabolic comorbidities may modify disease progression and contribute to a reduction in liverrelated events ( e.g. statins, aspirin, renin-angiotensinaldosterone modulators). 273,274”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [274]
The Results section ('Aspirin use and incident advanced fibrosis'; page unavailable) reports that daily aspirin use was associated with a lower risk of progression to advanced fibrosis in patients with NAFLD. This supports the aspirin example, but the paper does not establish that aspirin reduces liver-related events, and its findings do not support the statin or renin–angiotensin–aldosterone modulator examples. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · see citing works
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · see citing works
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · see citing works
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,198 · see citing works
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · see citing works
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143 · see citing works
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A. D., Murray, K. F., Tetri, B., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,561 · see citing works
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251 · see citing works
Lévesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,199 · see citing works
Lin, Z., Xin, Y., Dong, Q., Wang, Q., Jiang, X., Zhan, S.-H., Sun, Y. J., & Xuan, S. (2010) · Hepatology · doi:10.1002/hep.24105 · Cited by 1,071 · see citing works
Xiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895 · see citing works
Bibbins-Domingo, K. B., & on behalf of the U.S. Preventive Services Task Force* (2016) · Annals of Internal Medicine · doi:10.7326/m16-0577 · Cited by 853 · see citing works
Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update
Mosca, L. J., Benjamin, E. J., Berra, K. A., Bezanson, J. L., Dolor, R. J., Lloyd‐Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.005 · Cited by 783 · see citing works
Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.057 · Cited by 502 · see citing works
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., Kanemasa, K., et al. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-2 · Cited by 388 · see citing works
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s011 · Cited by 329 · see citing works
Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease
Börgeson, E., Johnson, A. M. F., Lee, Y. S., Till, A., Syed, G. H., Shah, S. T. A., Guiry, P. J., Dalli, J., Colas, R. A., Serhan, C. N., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.003 · Cited by 225 · see citing works
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
Simon, T. G., Ma, Y., Ludvigsson, J. F., Chong, D. Q., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., Zhang, X., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4154 · Cited by 210 · see citing works
Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164 · see citing works
Paik, Y. H., Kim, J. K., Lee, J. I., Kang, S. H., Kim, D. Y., An, S. H., Lee, S. J., Lee, D. K., Han, K.-H., Chon, C. Y., et al. (2009) · Gut · doi:10.1136/gut.2008.157420 · Cited by 126 · see citing works
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity
Knights, K., Mangoni, A. A., & Miners, J. O. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.120 · Cited by 115 · see citing works
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
Jiang, Z. G., Feldbrügge, L., Tapper, E. B., Popov, Y. V., Ghaziani, T., Afdhal, N. H., Robson, S. C., & Mukamal, K. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13515 · Cited by 106 · see citing works
Wong, R. J., Liu, B., & Bhuket, T. P. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14327 · Cited by 99 · see citing works
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Castéra, L. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562948 · Cited by 81 · see citing works
Major role of adipocyte prostaglandin E2 in lipolysis-induced macrophage recruitment
Hu, X., Cifarelli, V., Sun, S., Kuda, O., Abumrad, N. A., & Su, X. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066530 · Cited by 71 · see citing works
Mahady, S. E., Macaskill, P., Craig, J. C., Wong, G. L., Chu, C. W., Chan, H. L., George, J., & Wong, V. W. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.02.031 · Cited by 52 · see citing works
Tugendreich, S., Pearson, C. I., Sagartz, J. E., Jarnagin, K., & Kolaja, K. L. (2006) · Toxicologic Pathology · doi:10.1080/01926230600611752 · Cited by 48 · see citing works
Du, Y.-J. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.501 · Cited by 39 · see citing works
Kanai, S., Ishihara, K., Kawashita, E., Tomoo, T., Nagahira, K., Hayashi, Y., & Akiba, S. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229906 · Cited by 37 · see citing works
Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency
Feskanich, D., Bain, C., Chan, A. T., Pandeya, N., Speizer, F. E., & Colditz, G. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603996 · Cited by 32 · see citing works
Zhao, L., Gandhi, C. R., & Gao, Z. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02632.x · Cited by 18 · see citing works
Ishihara, K., Kanai, S., Tanaka, K., Kawashita, E., & Akiba, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.186 · Cited by 14 · see citing works
Devaki, P., & McCullough, A. J. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)34005-2 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 670 · see citing works
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
Foerster, F., Gairing, S., Müller, L., & Galle, P. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 265 · see citing works
Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults
Ruan, Z., Lu, T., Chen, Y., Yuan, M., Yu, H., Liu, R., & Xie, X. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.1609 · Cited by 249 · see citing works
Treatments for NAFLD: State of Art
Mantovani, A., & Dalbeni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052350 · Cited by 202 · see citing works
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Ismaiel, A., & Dumitrascu, D. L. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00202 · Cited by 196 · see citing works
Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02434-5 · Cited by 206 · see citing works
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 170 · see citing works
Yahoo, N., Dudek, M., Knolle, P. A., & Heikenwälder, M. F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.033 · Cited by 145 · see citing works
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
Thomas, J. A., Kendall, B. J., El‐Serag, H. B., Thrift, A. P., & Macdonald, G. A. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00275-3 · Cited by 140 · see citing works
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
Lange, N. F., Radu, P., & Dufour, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.025 · Cited by 137 · see citing works
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 133 · see citing works
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Mantovani, A., Byrne, C. D., Benfari, G., Bonapace, S., Simon, T. G., & Targher, G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.007 · Cited by 114 · see citing works
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103 · see citing works
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Simon, T. G., Wilechansky, R. M., Stoyanova, S., Grossman, A., Dichtel, L. E., Lauer, G. M., Miller, K. K., Hoshida, Y., Corey, K. E., Loomba, R. S., et al. (2024) · JAMA · doi:10.1001/jama.2024.1215 · Cited by 96 · see citing works
Platelets in chronic liver disease, from bench to bedside
Ramadori, P., Klag, T., Malek, N. P., & Heikenwälder, M. F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.001 · Cited by 88 · see citing works
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81 · see citing works
Chrysavgis, L., Giannakodimos, I., Diamantopoulou, P., & Cholongitas, Ε. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i3.310 · Cited by 80 · see citing works
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 82 · see citing works
Zhao, E., Cheng, Y., Yu, C., Li, H., & Fan, X. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2197652 · Cited by 72 · see citing works
Non-invasive biomarkers of Fontan-associated liver disease
Emamaullee, J. A., Khan, S., Weaver, C., Goldbeck, C. S., Yanni, G. S., Kohli, R., Genyk, Y., Zhou, S., Shillingford, N., Sullivan, P. M., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100362 · Cited by 70 · see citing works
Ballerini, P., Contursi, A., Bruno, A., Mucci, M., Tacconelli, S., & Patrignani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838079 · Cited by 69 · see citing works
Yang, K., & Song, M. J. (2023) · Nutrients · doi:10.3390/nu15183970 · Cited by 72 · see citing works
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
Ito, T., & Nguyen, M. H. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347959 · Cited by 61 · see citing works
NAFLD-Associated HCC: Progress and Opportunities
Geh, D., Anstee, Q. M., & Reeves, H. L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272213 · Cited by 61 · see citing works
Lemoinne, S., & Friedman, S. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.006 · Cited by 60 · see citing works
Ogresta, D., Mrzljak, A., Berković, M. C., Bilić-Čurčić, I., Stojsavljević, S., & Virović-Jukić, L. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00268 · Cited by 58 · see citing works
Memel, Z. N., Arvind, A., Moninuola, O., Philpotts, L. L., Chung, R. T., Corey, K. E., & Simon, T. G. (2020) · Hepatology Communications · doi:10.1002/hep4.1640 · Cited by 56 · see citing works
Miele, L., Alberelli, M. A., Martini, M., Liguori, A., Marrone, G., Cocomazzi, A., Vecchio, F. M., Landolfi, R., Gasbarrini, A., Grieco, A., et al. (2020) · Translational research · doi:10.1016/j.trsl.2020.11.003 · Cited by 53 · see citing works
Zhang, C., Liu, S., & Yang, M. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.808526 · Cited by 55 · see citing works
Shen, L., Saviano, A., Erstad, D. J., Hoshida, Y., Fuchs, B. C., Baumert, T. F., & Tanabe, K. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123817 · Cited by 49 · see citing works
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0239 · Cited by 52 · see citing works
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 49 · see citing works
Wang, W., Zhong, X., & Guo, J. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4947 · Cited by 47 · see citing works
Aspirin in Hepatocellular Carcinoma
Ricciotti, E., Wangensteen, K. J., & FitzGerald, G. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0758 · Cited by 44 · see citing works
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45 · see citing works
Till Death Do Us Part—The Multifaceted Role of Platelets in Liver Diseases
Mußbacher, M., Brunnthaler, L., Panhuber, A., Starlinger, P. P., & Assinger, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063113 · Cited by 41 · see citing works
Chen, Y.-W., Diamante, G., Ding, J., Nghiem, T. X., Yang, J., Ha, S. M., Cohn, P., Arneson, D. V., Blencowe, M., García, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104052 · Cited by 41 · see citing works
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 42 · see citing works
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 42 · see citing works
Aspirin attenuates liver fibrosis by suppressing TGF‑β1/Smad signaling
Sun, Y., Liu, B., Xie, J., Jiang, X., Xiao, B., Hu, X., & Xiang, J. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12697 · Cited by 39 · see citing works
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
Teng, Y., Xie, S., Guo, P., Deng, Z.-J., Zhang, Z., Gao, W., Zhang, W.-G., & Zhong, J.-H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00586 · Cited by 36 · see citing works
Lee, T.-Y., Hsu, Y.-C., Ho, H., Lin, J.-T., Chen, Y.-J., & Wu, C.-Y. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102065 · Cited by 38 · see citing works
Zhang, H., Yang, S., Wang, J., & Jiang, Y. (2021) · Cancers · doi:10.3390/cancers13071738 · Cited by 38 · see citing works
de Vries, M., El-Morabit, F., van Erpecum, K. J., Westerink, J., Bac, S. T., Kaasjager, K. A. H., & de Valk, H. W. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.025 · Cited by 35 · see citing works
Minciună, I., Taru, M. G., Procopeț, B., & Ştefănescu, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051406 · Cited by 34 · see citing works
Boccatonda, A., Cane, L. D., Marola, L., D'Ardes, D., Lessiani, G., di Gregorio, N., Ferri, C., Cipollone, F., Serra, C., Santilli, F., et al. (2024) · Life · doi:10.3390/life14040473 · Cited by 35 · see citing works
Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
Shroff, H., & VanWagner, L. B. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00530-0 · Cited by 30 · see citing works
Pasqua, L. G. D., Cagna, M., Berardo, C., Vairetti, M., & Ferrigno, A. (2022) · Biomedicines · doi:10.3390/biomedicines10010194 · Cited by 32 · see citing works
Platelets in Non-alcoholic Fatty Liver Disease
Dalbeni, A., Castelli, M., Zoncapè, M., Minuz, P., & Sacerdoti, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842636 · Cited by 34 · see citing works
Yang, L., Hao, Y., Boeckmans, J., Rodrigues, R., & He, Y. (2023) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2023.108353 · Cited by 27 · see citing works
The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
Malladi, N., Alam, M. J., Maulik, S. K., & Banerjee, S. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106766 · Cited by 30 · see citing works
Liu, Y., Li, N., Jia, Y., Tan, A., Duan, L., Lu, Y., & Zhao, J. (2020) · Aging · doi:10.18632/aging.103002 · Cited by 29 · see citing works
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Lee, H. A., Chang, Y. W., Sung, P. S., Yoon, E. L., Lee, H. W., Yoo, J., Lee, Y., An, J., Song, D. S., Cho, Y. Y., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0186 · Cited by 30 · see citing works
Grattagliano, I., Ciaula, A. D., Baj, J., Molina‐Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1433-4_12 · Cited by 26 · see citing works
The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
Maciejewska, D., Stachowska, E., Hawryłkowicz, V., Stachowska, L., & Prowans, P. (2021) · Biomolecules · doi:10.3390/biom11070937 · Cited by 26 · see citing works
Merat, S., Jafari, E., Radmard, A. R., Khoshnia, M., Sharafkhah, M., Baygi, A. N., Marshall, T. P., Khuzani, A. S., Cheng, K. K., Poustchi, H., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab919 · Cited by 26 · see citing works
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
Jokinen, M. J., & Luukkonen, P. K. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.003 · Cited by 24 · see citing works
Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 24 · see citing works
The Potential Use of Cannabis in Tissue Fibrosis
Pryimak, N., Zaiachuk, M., Kovalchuk, O., & Kovalchuk, I. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.715380 · Cited by 23 · see citing works
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 25 · see citing works
Arvind, A., Osganian, S. A., Sjoquist, J. A., Corey, K. E., & Simon, T. G. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.08.001 · Cited by 23 · see citing works
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Yu, S., Wang, J., Zheng, H., Wang, R., Johnson, N. L., Li, T., Li, P., Lin, J., Li, Y., Jin, Y., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s377768 · Cited by 23 · see citing works
Clayton‐Chubb, D., Roberts, S. K., Majeed, A., Woods, R. L., Tonkin, A., Nelson, M. R., Chan, A. T., Ryan, J. L., Tran, C., Hodge, A. D., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01435-2 · Cited by 26 · see citing works
Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease
Yin, H., Shi, A., & Wu, J. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s367483 · Cited by 22 · see citing works
van den Hoek, A. M., Pieterman, E. J., van der Hoorn, J. W., Iruarrizaga‐Lejarreta, M., Alonso, C., Verschuren, L., Skjæret, T., Princen, H. M. G., & Fraser, D. A. (2019) · Hepatology Communications · doi:10.1002/hep4.1453 · Cited by 22 · see citing works
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 20 · see citing works
Ferri, F., Mischitelli, M., Tozzi, G., Messina, E., Mignini, I., Mazzuca, S., Pellone, M., Parisse, S., Marrapodi, R., Visentini, M., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000116 · Cited by 19 · see citing works
Antiplatelet drugs and liver fibrosis
Czajka, P., Przybyłkowski, A. M., Nowak, A., Postula, M. A., Wolska, M., Mirowska-Guzel, D. M., Członkowska, A., & Eyileten, C. (2021) · Platelets · doi:10.1080/09537104.2021.1883574 · Cited by 19 · see citing works
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 18 · see citing works
Xiao, S., Liu, Y., Fu, X., Chen, T., & Xie, W. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.031 · Cited by 17 · see citing works
Stokman, G., van den Hoek, A. M., Thorbek, D. D., Pieterman, E. J., Veidal, S. S., Basta, B. N., Iruarrizaga‐Lejarreta, M., van der Hoorn, J. W., Verschuren, L., Berbée, J. F. P., et al. (2020) · Liver International · doi:10.1111/liv.14643 · Cited by 17 · see citing works
Oral, A., Şahin, T., Türker, F., & Koçak, E. (2019) · Medical Science Monitor · doi:10.12659/msm.920172 · Cited by 17 · see citing works
Arvanitakis, K., Papadakos, S. P., Lekakis, V., Koufakis, T., Lempesis, I. G., Papantoniou, E., Kalopitas, G., GEORGAKOPOULOU, V. E., Stergiou, I. Ε., Theocharis, S. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914704 · Cited by 15 · see citing works
PGE2 synthesis and signaling in the liver physiology and pathophysiology: An update
Qiang, E., & Xu, H. (2024) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2024.106875 · Cited by 15 · see citing works
Thongtan, T., Deb, A., Vutthikraivit, W., Laoveeravat, P., Mingbunjerdsuk, T., Islam, S. R., & Islam, E. A. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01230-3 · Cited by 15 · see citing works
Aspirin is associated with a reduced incidence of liver disease in men
Vell, M. S., Krishnan, A., Wangensteen, K. J., Serper, M., Seeling, K. S., Hehl, L., Rendel, M. D., Zandvakili, I., Vujković, M., Scorletti, E., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000268 · Cited by 14 · see citing works
Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
Ramadan, M. S., Russo, V., Nigro, G., Durante‐Mangoni, E., & Zampino, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081569 · Cited by 15 · see citing works
How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease
Ismaiel, A., & Dumitrascu, D. L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001174 · Cited by 14 · see citing works
Seifert, L. L., Schindler, P., Sturm, L., Gu, W., Seifert, Q. E., Weller, J. F., Jansen, C., Praktiknjo, M., Meyer, C. H., Schoster, M., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10330-x · Cited by 14 · see citing works
Violi, F., Pastori, D., Pignatelli, P., & Cammisotto, V. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.003 · Cited by 12 · see citing works
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Cho, Y., Kim, B. H., & Park, J. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0360 · Cited by 12 · see citing works
Small but Mighty: Platelets in NASH and Other Chronic Liver Diseases
Hilscher, M. B., & Shah, V. H. (2020) · Hepatology · doi:10.1002/hep.31101 · Cited by 11 · see citing works
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
Fraser, D. A., Harrison, S. A., & Schuppan, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159804 · Cited by 10 · see citing works
Bitto, N., Ghigliazza, G., Lavorato, S., Caputo, C., & Mura, V. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030934 · Cited by 11 · see citing works
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 11 · see citing works
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 8 · see citing works
Suzuki, A., Karachaliou, G. S., Perkins, A. M., Dorn, C. A., Reeves, R., Arnold, T., Bashir, M. R., Efird, J. T., Abdelmalek, M. F., & Diehl, A. M. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103431 · Cited by 9 · see citing works
Samuel, S., Abulawi, A., & Malik, R. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030018 · Cited by 9 · see citing works
An Overview of New Acetamide Derivatives in COX-II Inhibitors
Atrushi, K. S., Ameen, D. M., & Abachi, F. T. (2023) · Pharmaceutical Sciences and Drug Design · doi:10.51847/4i0ldw0c63 · Cited by 7 · see citing works
Sherman, M. S., Challa, P. K., Przybyszewski, E. M., Wilechansky, R. M., Uche-Anya, E. N., Ott, A. T., McGoldrick, J., Goessling, W., Khalili, H., & Simon, T. G. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000403 · Cited by 7 · see citing works
Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis
Ahmed, T., Grigorian, A. Y., & Messerli, A. W. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00478-6 · Cited by 7 · see citing works
Meinel, K., Korak, F., Dusleag, M., Strini, T., Baumgartner, D., Burmas, A., Sallmon, H., Zieger, B., Schlagenhauf, A., & Köestenberger, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031240 · Cited by 6 · see citing works
New evidence of cross-disease communication between heart and liver.
Marjot, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.034 · Cited by 6 · see citing works
Lambooij, J. M., Chavanelle, V., Vallier, M., van der Zande, H. J. P., Otero, Y. F., Otto, F., Schuurman, R., Joubioux, F. L., Maugard, T., Giera, M. A., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00033-z · Cited by 6 · see citing works
Koufakis, T., Popovic, D. S., Papadopoulos, C. E., Γιουλεμέ, Ό., & Doumas, M. N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2312239 · Cited by 6 · see citing works
Fu, Y., Jiang, C. Q., Li, Z., Shi, X., Lv, P., & Zhang, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1473487 · Cited by 6 · see citing works
Wang, Y., Chen, K., Yu, J., Tu, Y., Zhao, Y., Zhang, Y., Hu, Y., Yang, H. J., Yan, H., & Zheng, C. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04018-3 · Cited by 6 · see citing works
Nonalcoholic Fatty Liver Disease
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_9 · Cited by 6 · see citing works
- Authors
- Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Corey, Kathleen E.
- ORCID
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 17
- Issue
- 13
- Pages
- 2776-2784.e4
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC6842070
- OpenAlex
- W2944339954
- Cited by
- 180
- References
- 36
- Citations by year
- 2026: 10 · 2025: 28 · 2024: 30 · 2023: 25 · 2022: 27 · 2021: 30 · 2020: 20 · 2019: 10
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (K24DK078772, K23DK122104, K23DK099422, K24DK098311, R01 CA137178, 5P30DK046200-25)
- NCI
- AASLD
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- aspirin, non-alcoholic fatty liver disease, liver fibrosis progression, nonalcoholic steatohepatitis, nonsteroidal anti-inflammatory drugs, NSAID use, FIB-4, NAFLD fibrosis score, aspartate aminotransferase to platelet ratio index
- MeSH terms
- Duration of Therapy, Adult, Aged, Aspartate Aminotransferases, Aspirin, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Platelet Aggregation Inhibitors, Platelet Count, Prospective Studies, Cohort Studies, Multivariate Analysis, Logistic Models, Proportional Hazards Models, Disease Progression, Non-alcoholic Fatty Liver Disease, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
